These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
366 related items for PubMed ID: 1668604
1. Cardiac and vascular effects of NZ-105, a novel dihydropyridine derivative, in vitro. Masuda Y, Iwama T, Yamashita T, Sakai T, Hibi M, Tanaka S, Shigenobu K, Kasuya Y. Arch Int Pharmacodyn Ther; 1991; 314():57-73. PubMed ID: 1668604 [Abstract] [Full Text] [Related]
2. Vasorelaxing and receptor binding properties of NZ-105, a novel dihydropyridine derivative, in isolated rabbit aorta. Masuda Y, Iwama T, Yamashita T, Sakai T, Hibi M, Tanaka S, Shigenobu K, Kasuya Y. Arch Int Pharmacodyn Ther; 1991; 312():86-103. PubMed ID: 1663336 [Abstract] [Full Text] [Related]
3. Cardiovascular selectivity of 1,4-dihydropyridine derivatives, efonidipine (NZ-105), nicardipine and structure related compounds in isolated guinea-pig tissues. Masuda Y, Miyajima M, Shudo C, Tanaka S, Shigenobu K, Kasuya Y. Gen Pharmacol; 1995 Mar; 26(2):339-45. PubMed ID: 7590084 [Abstract] [Full Text] [Related]
4. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Guarneri L, Angelico P, Ibba M, Poggesi E, Taddei C, Leonardi A, Testa R. Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512 [Abstract] [Full Text] [Related]
5. Effects of nilvadipine on the cardiovascular system in experimental animals. Ohtsuka M, Koibuchi Y, Sakai S, Tsujioka K, Fujiwara T, Ozaki T, Maeda K, Motoyama I, Horiai H, Ono T. Arzneimittelforschung; 1988 Nov; 38(11):1605-18. PubMed ID: 3214444 [Abstract] [Full Text] [Related]
7. Antihypertensive and cardiovascular effects of the new dihydropyridine derivative methyl (E)-3-phenyl-2-propen-1-yl-1,4-dihydro-2,6-dimethyl- 4-(3-nitrophenyl)pyridine-3,5-dicarboxylate. Yamaura T, Kase N, Kita H, Uematsu T. Arzneimittelforschung; 1986 Nov; 36(1):29-34. PubMed ID: 3754142 [Abstract] [Full Text] [Related]
15. Cerebrovascular selectivity and vasospasmolytic action of the novel calcium antagonist (+/-)-(E)-1-(3-fluoro-6, 11-dihydrodibenz[b,e]oxepin-11-yl)-4-(3-phenyl-2-propenyl)-piperazine dimaleate in isolated cerebral arteries of the rabbit and dog. Minato H, Hashizume M, Masuda Y, Fujitani B, Hosoki K. Arzneimittelforschung; 1997 Apr; 47(4):339-46. PubMed ID: 9150852 [Abstract] [Full Text] [Related]